At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 72 enrolled
Drug / intervention
Tiotropium Respimat® (T1) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Two-way Crossover Study to Compare Patient Acceptability/Preference of Tiotropium Respimat® With Tiotropium Handihaler® in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 4 clinical trial evaluating Tiotropium Respimat® (T1) and Tiotropium Handihaler® (T2) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 72 participants across 8 sites.
Detailed Summary
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the superiority of Respimat®.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartNov 2019
Primary CompletionOct 2021
Study CompletionNov 2021
TodayJul 2026
First PostedMay 28, 2019
Enrollment StartNov 25, 2019
Primary CompletionOct 19, 2021
Study CompletionNov 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.1 years ago
Interventions
Tiotropium Respimat® (T1)drug
inhalation solution
Tiotropium Handihaler® (T2)drug
Inhalation Powder